Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rifaximin 550 MG Clear all
Completed Phase 2 Interventional Results available

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

NCT03712280
View directory record Official record
Conditions
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
Interventions
MNK6106, Rifaximin
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing

NCT03219528
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin 550 MG, Low FODMAP Diet
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 26, 2026, 10:38 AM EDT
Withdrawn Early Phase 1 Interventional

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

NCT02738905
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rifaximin
Drug
Lead sponsor
Jason Stubbs, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00731679
View directory record Official record
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Hueytown, Alabama • Phoenix, Arizona • Sierra Vista, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

NCT00269412
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
67
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

NCT01846663
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

NCT01662791
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rifaximin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 26, 2026, 10:38 AM EDT
Withdrawn Phase 2 Interventional

Rifaximin Treatment of Papulopustular Rosacea

NCT01359228
View directory record Official record
Conditions
Rosacea
Interventions
Rifaximin (XIFAXAN), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 26, 2026, 10:38 AM EDT
Not listed Phase 2 Interventional

Rifaximin to Modify the Disease Course in Sickle Cell Disease

NCT03719729
View directory record Official record
Conditions
Sickle Cell Disease, Antibiotics
Interventions
Rifaximin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549
View directory record Official record
Conditions
Crohn Disease, Diabetic Gastroparesis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 26, 2026, 10:38 AM EDT
Not listed Phase 2 Interventional

Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

NCT01603108
View directory record Official record
Conditions
Hepatitis C
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Xifaxan to Treat Patients With PSC

NCT01695174
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Xifaxan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

NCT00956397
View directory record Official record
Conditions
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
Interventions
Rifaximin, Lactulose Breath Test, Placebo
Drug · Procedure
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 26, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Rifaximin on Visceral Hypersensitivity

NCT03462966
View directory record Official record
Conditions
Visceral Hypersensitivity, Irritable Bowel Syndrome
Interventions
Rifaximin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00724126
View directory record Official record
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
88
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

NCT01466595
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Rifaximin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

NCT01543178
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
open-label rifaximin, double-blind placebo, double-blind rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
293
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 26, 2026, 10:38 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

NCT03818672
View directory record Official record
Conditions
Severe Hepatic Impairment
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Trial of Rifaximin in Probable Alzheimer's Disease

NCT03856359
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rifaximin 550 milligrams (MG)
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 26, 2026, 10:38 AM EDT
Recruiting Phase 4 Interventional

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

NCT06312683
View directory record Official record
Conditions
Pouchitis
Interventions
Rifaximin 550 MG Oral Tablet [XIFAXAN]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Not applicable Interventional Results available

Gulf War Digestive Health Study

NCT00680836
View directory record Official record
Conditions
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 72 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Not applicable Interventional Results available

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

NCT00945334
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Neomycin, Placebo, Rifaximin
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 26, 2026, 10:38 AM EDT
Not listed Phase 4 Interventional

Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet

NCT04674176
View directory record Official record
Conditions
Weight Loss
Interventions
Rifaximin
Drug
Lead sponsor
Bayhealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dover, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 26, 2026, 10:38 AM EDT